PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50326F80006Atropine 0.4mgml x 20ml SOLN. for — Fresenius Kabi, LLC

Fresenius Kabi, LLC holds $98.3M across 1,575 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award under parent 36F79725D0145. Competition previously drew 2 offers. Recompete timing centers on the Jul 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Fresenius Kabi, LLC

Recipient

Jul 29, 2027

PoP end

$7.9M

Obligated

$7.9M

Potential

325412

NAICS

6505

PSC

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Fresenius Kabi, LLC — $90

Contract facts

Federal

Contract number75A50326F80006

Also listed as36F79725D0145-75A50326F80006

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentFresenius Kabi, LLC

CAGE57KZ6

UEIC2TRNWNQKMD6

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79725D0145

Place of performanceLONG GROVE IL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJul 30, 2026

PoP end (current)Jul 29, 2027

Obligated$7.9M

Current value$7.9M

Potential value$7.9M

ATROPINE 0.4MGML X 20ML SOLN. FOR INJ., MULTI-DOSE VIALS 8MG AND MIDAZOLAM SOLN. FOR INJ., 5MG/ML, MULTI-DOSE VIALS EO 14398 is a federal award for Aspr/Orm-Sns held by Fresenius Kabi, LLC. Estimated value $7.9M ($7.9M obligated). Current period of performance ends Jul 29, 2027. Last award drew 2 bidders. Place of performance: LONG GROVE IL.

ATROPINE 0.4MGML X 20ML SOLN. FOR INJ., MULTI-DOSE VIALS 8MG AND MIDAZOLAM SOLN. FOR INJ., 5MG/ML, MULTI-DOSE VIALS EO 14398

Recompete timing

Public

● Expiring in 342 days

Current PoP ends Jul 29, 2027 (342 days remaining). Agencies typically plan 12–18 months ahead — at 11.2 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Fresenius Kabi, LLC — $98.3M obligated across 1,575 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($98.3M) · all agencies

Department of Health and Human Services (HHS)$94.1M · 96%Department of Defense (DOD)$4.2M · 4%

Open full company profile →

Related awards

Same parent · incumbent

SPE2D025F0535

8511525788!OTHER MEDICAL

$1.4M

Aug 31, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50326F80006?

75A50326F80006 (Atropine 0.4mgml x 20ml SOLN. for) is a Aspr/Orm-Sns award with a potential value of $7.9M, currently held by Fresenius Kabi, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50326F80006?

Aspr/Orm-Sns awarded 75A50326F80006 to Fresenius Kabi, LLC (potential $7.9M).

Who is the incumbent on 75A50326F80006?

Fresenius Kabi, LLC is the incumbent with $98.3M across 1575 related awards in SCOUT’s public footprint. The current period of performance ends Jul 29, 2027.

When does Fresenius Kabi, LLC’s 75A50326F80006 come up for recompete?

SCOUT tracks a period-of-performance end of Jul 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 18, 2026 · refreshed monthlyLatest procurement action Jul 29, 2026